Literature DB >> 17589368

Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.

Kyeen M Andersson1, Douglas K Owens, Eftyhia Vardas, Glenda E Gray, James A McIntyre, A David Paltiel.   

Abstract

We developed a mathematical model to simulate the impact of various partially effective preventive HIV vaccination scenarios in a population at high risk for heterosexually transmitted HIV. We considered an adult population defined by gender (male/female), disease stage (HIV-negative, HIV-positive, AIDS, and death), and vaccination status (unvaccinated/vaccinated) in Soweto, South Africa. Input data included initial HIV prevalence of 20% (women) and 12% (men), vaccination coverage of 75%, and exclusive male negotiation of condom use. We explored how changes in vaccine efficacy and postvaccination condom use would affect HIV prevalence and total HIV infections prevented over a 10-year period. In the base-case scenario, a 40% effective HIV vaccine would avert 61,000 infections and reduce future HIV prevalence from 20% to 13%. A 25% increase (or decrease) in condom use among vaccinated individuals would instead avert 75,000 (or only 46,000) infections and reduce the HIV prevalence to 12% (or only 15%). Furthermore, certain combinations of increased risk behavior and vaccines with <43% efficacy could worsen the epidemic. Even modestly effective HIV vaccines can confer enormous benefits in terms of HIV infections averted and decreased HIV prevalence. However, programs to reduce risk behavior may be important components of successful vaccination campaigns.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589368      PMCID: PMC3570247          DOI: 10.1097/QAI.0b013e31812506fd

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  52 in total

1.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

Authors:  R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement.

Authors:  W Pequegnat; M Fishbein; D Celentano; A Ehrhardt; G Garnett; D Holtgrave; J Jaccard; J Schachter; J Zenilman
Journal:  Sex Transm Dis       Date:  2000-03       Impact factor: 2.830

3.  What can be achieved with an HIV vaccine?

Authors:  J A Levy
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

Review 4.  Social factors that make South African women vulnerable to HIV infection.

Authors:  Leáne Ackermann; KlerkGerhardtW de
Journal:  Health Care Women Int       Date:  2002-02

5.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Authors:  Dilys Morgan; Cedric Mahe; Billy Mayanja; J Martin Okongo; Rosemary Lubega; James A G Whitworth
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

6.  The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model.

Authors:  Elizabeth Bogard; Karen M Kuntz
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

7.  Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

Authors:  S M Blower; K Koelle; D E Kirschner; J Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

8.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

9.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.

Authors:  S A Allen; R Musonda; S Trask; B H Hahn; H Weiss; J Mulenga; F Kasolo; S H Vermund; G M Aldrovandi
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

10.  Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.

Authors: 
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

View more
  16 in total

1.  Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission.

Authors:  Kyeen M Andersson; Douglas K Owens; A David Paltiel
Journal:  AIDS Behav       Date:  2011-07

2.  The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Authors:  Elisa F Long; Douglas K Owens
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

3.  The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.

Authors:  Kyeen M Andersson; A David Paltiel; Douglas K Owens
Journal:  Vaccine       Date:  2011-07-05       Impact factor: 3.641

4.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

5.  Relationship-level analysis of drug users' anticipated changes in risk behavior following HIV vaccination.

Authors:  April M Young; Daniel S Halgin; Jennifer R Havens
Journal:  AIDS Care       Date:  2015-03-02

6.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Authors:  Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

7.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

8.  HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Authors:  Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau
Journal:  Vaccine       Date:  2017-12-11       Impact factor: 3.641

9.  Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Authors:  Maria Goretti P Fonseca; Steven Forsythe; Alexandre Menezes; Shilpa Vuthoori; Cristina Possas; Valdiléa Gonçalves Veloso; Valdiléa Veloso; Francisca de Fátima Lucena; John Stover
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

10.  Network effects of risk behavior change following prophylactic interventions.

Authors:  Rajmohan Rajaraman; Zhifeng Sun; Ravi Sundaram; Anil Kumar S Vullikanti
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.